STOCKHOLM, Sweden, 18th October 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that a new agreement has been reached with RELIFE S.r.l. regarding the company's psoriasis project. The new terms relate to geographic expansion through the addition of the Asia-Pacific region and an updated timeline. Lipidor has previously signed a […]
STOCKHOLM, Sweden, 20th September 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) has signed an agreement with Cliantha Research to conduct a phase III study with the drug candidate AKP02G2, for the treatment of psoriasis. The study is expected to begin recruitment of patients in the first half of 2024 and Lipidor […]
STOCKHOLM, den 20 september 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) har tecknat ett avtal med Cliantha Research för genomförande av en fas III studie med läkemedelskandidaten AKP02G2, för behandling av psoriasis. Studien förväntas påbörja rekrytering av patienter under det första halvåret 2024 och vi hoppas kunna presentera studieresultat redan i […]
STOCKHOLM, Sweden, 22nd June 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att Läkemedelsverket bedömer att AKP02G2, den modifierade versionen av bolagets läkemedelskandidat AKP02 för behandling av psoriasis, kan användas i en ny klinisk Fas III-studie. Det innebär att inga ytterligare kliniska studier med AKP02G2 kommer att behövas innan en […]
STOCKHOLM, Sweden, 22nd June 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the Swedish Medical Products Agency (“MPA”) considers that AKP02G2, a modified version of the company's drug candidate AKP02 for the treatment of psoriasis, can be used in a new Phase III clinical study. This means that no […]
STOCKHOLM, Sweden, 26th May 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) is targeting a new Phase III study of the drug candidate AKP02 in 2024. Data from the earlier completed clinical study with AKP02 has been analyzed, and a way forward is clear. On 28th October 2022, Lipidor announced that the […]
STOCKHOLM den 26 maj 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) siktar på en ny Fas III-studie med AKP02 under 2024. Data från den tidigare genomförda kliniska studien med läkemedelskandidaten AKP02, har analyserats och en väg framåt är tydlig. Den 28 oktober 2022 meddelade Lipidor att kombinationspreparatet AKP02 för behandling av […]
STOCKHOLM, 15 November 2022 – On October 28, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced that the Phase III study with the combination preparation AKP02 did not achieve the criterion of equivalent therapeutic efficacy in the treatment of psoriasis compared to the market-leading reference product. However, the study results show that AKP02 […]
STOCKHOLM den 15 november 2022 – Den 28 oktober meddelade Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) att Fas III-studien med kombinationspreparatet AKP02 inte uppnådde kriteriet likvärdig terapeutisk effekt (”non-inferiority”) vid behandling av psoriasis jämfört med den marknadsledande referensprodukten. Studieresultatet visar dock att AKP02 har god effekt i jämförelse med placebo och det […]
STOCKHOLM 28 October 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study did not achieve the study's primary goal of achieving non-inferiority of therapeutic efficacy in the treatment of psoriasis compared to the reference product. However, AKP02 shows clearly better efficacy than placebo. The study […]